Wednesday, March 01, 2017 11:06:20 AM
http://finance.yahoo.com/news/decn-victorious-u-supreme-court-142000730.html
SCOTUS Denial of J&J Claims Finally Opens Doors to Sales in the EU with Less Fear of Legal Repraisal
LOS ANGELES, CA / ACCESSWIRE / March 1, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator, and the exclusive worldwide sales, service, and regulatory processes agent for GenStripTM 50 and the GenUltimate!TM glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the recently completed GenSure!TM and GenChoice!TM glucose test strips targeted to the U.S. and/or developing world markets, today updates investors regarding its litigation against J&J/Lifescan in regards to U.S. Patent No. 7,250,105 (the "105" patent) and this litigation's final conclusion.
Decision Diagnostics' company shareholders have been spectators to years of unwarranted legal attacks engendered by J&J/Lifescan in an illicit effort to prevent Genstrip and GenUltimate, the Pharma Tech Solutions which feature rich and inexpensive blood glucose test strips, from disrupting their blood glucose test strip monopoly.
As had been previously announced, after a consistent series of victories in the Federal courts dating back to 2013, the U.S. Appeals Court for the Federal Circuit on May 10, 2016 terminated the J&J/Lifescan meritless legal attacks by a rejection of the J&J/Lifescan petition for en-banc rehearing filed in a desperate final attempt to preserve their foundational "105" patent. That ruling, and the Appeals Court Mandate that followed nine days later, rendered any such claims to patentability null and void.
Inexplicably, J&J/Lifescan opted to respond to the unequivocal and unambiguous Federal Circuit Court ruling by directing its attorneys to petition the Supreme Court of the United States by filing a Writ of Certiorari. Had the Writ been granted, it would have compelled the Circuit Court to transfer their case related legal records to the Supreme Court for a review of the ruling by the panel of judges in the USPTO. That Writ is issued solely at the discretion of the Supreme Court and when at least three of the SCOTUS justices believe the review is warranted based on a sufficiently significant federal question.
Keith Berman, Principal Executive of DECN, stated, "This is all too monotonously familiar to everyone involved; we keep winning and J&J/Lifescan keeps filing additional appeals. Fortunately, they have now run out of courts. There is nowhere else for them to turn in their fumbling attempts to perpetuate this frivolous litigation. This is now and forever formally concluded. We have unconditionally won our right to market Genstrip 50 and GenUltimate wherever and to whomever we choose. The company is a winner, our shareholders are winners, and, most importantly, the global diabetic population is the biggest winner. J&J/Lifescan is, of course, the loser."
http://www.scotusblog.com/case-files/cases/lifescan-scotland-ltd-v-pharmatech-solutions-inc/
The J&J/Lifescan petition to the SCOTUS was circulated to the justices for their consideration on January 6, 2017. On January 9, 2017 the court decided that the petition failed to reach the minimal legal threshold for review and formally denied the J&J/Lifescan attorney petition for filing of a Writ of Certiorari.
Forward-Looking Statements:
This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of November 29, 2016, regarding the Company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION
Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
info@decisiondiagnostics.com
www.genultimate.com
www.decisiondiagnostics.com
SOURCE: Decision Diagnostics Corp.
“I Think, Therefore I am”
Recent JNJ News
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- US Index Futures See Gains, Oil Prices Dip • IH Market News • 04/17/2024 10:59:02 AM
- U.S. Stocks Finish Lackluster Session Narrowly Mixed • IH Market News • 04/16/2024 08:33:00 PM
- CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 02:46:00 PM
- J&J’s Q1 2024 sales rise 2.3% to $21.4 billion • IH Market News • 04/16/2024 01:52:44 PM
- Dow Looks To Snap Six-Day Losing Streak As UnitedHealth Surges • IH Market News • 04/16/2024 01:09:47 PM
- U.S. Index Futures Signal Mixed Trading, Oil Prices Dip • IH Market News • 04/16/2024 11:19:33 AM
- Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News • IH Market News • 04/16/2024 11:18:19 AM
- Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% • Business Wire • 04/16/2024 10:25:00 AM
- Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 10:20:00 AM
- U.S. Stocks Extend Sell-Off As Treasury Yields Surge After Retail Sales Data • IH Market News • 04/15/2024 08:38:32 PM
- Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/08/2024 10:06:00 PM
- CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy • PR Newswire (US) • 04/06/2024 03:21:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc. • PR Newswire (US) • 04/05/2024 06:55:00 PM
- Apple Terminates 614 Employees, Disney Unveils June Crackdown on Password Sharing, and More Updates • IH Market News • 04/05/2024 11:38:57 AM
- Johnson & Johnson to Acquire Shockwave Medical • Business Wire • 04/05/2024 10:31:00 AM
- Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation • Business Wire • 04/04/2024 10:01:00 PM
- Johnson & Johnson to Participate in the BofA Securities Health Care Conference • Business Wire • 04/02/2024 08:30:00 PM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge • GlobeNewswire Inc. • 03/12/2024 01:15:00 PM
- Johnson & Johnson to Host Investor Conference Call on First-Quarter Results • Business Wire • 03/11/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:58:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:58:22 PM
- Johnson & Johnson Completes Acquisition of Ambrx • Business Wire • 03/07/2024 01:33:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM